Investment Adviser Disclosures

For Corporates
Analyzing Healthcare M&A Trends: Q1 2024 Insights
Healthcare M&A activity remained robust in the first quarter of 2024, with 29 transactions vs. 28 in 2023. Biopharma was the most active healthcare subsector, representing 45% of deal volume, while Services activity remained dampened despite notable transactions such as Novo Holdings’ acquisition of Catalent. We expect Biopharma M&A activity to remain robust as large pharmaceutical companies attempt to fill revenue and pipeline gaps via acquisitions of late- or commercial-stage companies. We expect pre-commercial biopharma companies to continue pursue strategic alternatives, including mergers, private company mergers and cash-out transactions as a result of the dynamic capital markets environment.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Investment Adviser Disclosures

Leerink Pharmaceutical Investments LLC
Leerink Revelation Partners LLC
Leerink Transformation Partners LLC

Leerink Pharmaceutical Investments LLC, Leerink Revelation Partners LLC and Leerink Transformation Partners LLC (collectively “Leerink Advisers”) are investment adviser affiliates of Leerink Partners LLC. They are registered with the SEC as Investment Advisers, are separate legal entities, and conduct a separate business from the broker/dealer activity of Leerink Partners LLC.

Investment Adviser Disclosures

Partner With Us

Contact Us